January 12, 2021
CMIC Co., Ltd.
Tokyo- January 21, 2021 –CMIC Co Ltd. (henceforth “CMIC”) has joined the Decentralized Trials & Research Alliance (henceforth “DTRA”), an alliance seeking to accelerate the broad adoption of decentralized clinical trials, as a Founding Company. DTRA is an alliance that was convened in the U.S. on December 10, 2020, in order to advance decentralized clinical trials by uniting mainly U.S.-based healthcare companies, regulators, patient groups and research organizations. As a Founding Company, CMIC will join the DTRA Leadership Council, effectively advancing decentralized trials in Japan by strengthening its connection with respective organizations and companies in the U.S.
“By joining the Leadership Council, CMIC will be able to study real-world examples of decentralized clinical trials that are led in the U.S., and network with U.S. organizations. Through this, CMIC will be able to formulate realistic and efficient studies within the Japanese clinical trial environment, and propose solutions for challenges that arise during a trial. As a member of DTRA, we will leverage the latest global digital health technology to the fullest, and contribute to smooth decentralized trial conduct in Japan. Furthermore, as the largest Japanese CRO with a broad Asian footprint, we will bring our decentralized trial adoption experiences, trends and needs of the fast-growing Asian market into DTRA, in order to facilitate the development of future global standards.” said Toru Fujieda, President of CMIC Co., Ltd.
To learn more about our decentralized clinical trial services, please contact us at email@example.com
The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.
■About CMIC group
CMIC Group was founded in 1992 as the first Contract Research Organization (CRO) in Japan. Today CMIC Group is the largest clinical CRO in Japan with global footprint, providing comprehensive services in drug development, clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge drug development and manufacturing needs in the US, Europe, Japan and broader Asia. CMIC Group has over 7,000 employees and 25 sites globally. For more information about CMIC Group and services, please visit our website. https://en.cmicgroup.com/
CMIC HOLDINGS Co., LTD. PR group